ABCB1基因多态性与五酯胶囊对他克莫司增效作用的相关性研究

Correlation between ABCB1 Polymorphisms and Synergistic Effects of Wuzhi Capsules on Tacrolimus

目的:研究五酯胶囊对他克莫司增效作用与ABCB1基因多态性的相关性研究。方法:通过聚合酶链反应-限制性片段长度多态性(PCR-RFLP)方法测定ABCB1 1236C>T(rs1128503)、ABCB1 2677G>T/A(rs2032582)和ABCB1 3435C>T(rs1045642)基因型,使用化学发光微粒子免疫分析技术(CMIA)检测他克莫司C_0。采用协方差分析考察不同组别患者他克莫司C_0/D的差异。结果:无论是单独使用他克莫司,还是他克莫司与五酯胶囊合用,ABCB1 1236C>T、ABCB1 2677G>T/A、ABCB1 3435C>T不同基因型及单倍型组的他克莫司C_0/D均无显著差异(P>0.05)。结论:五酯胶囊对他克莫司的增效作用与ABCB1 1236C>T、ABCB1 2677G>T/A、ABCB1 3435C>T基因多态性无关。

Objective： To investigate the correlation of ABCB1 polymorphisms and the synergistic effect of Wuzhi capsules on tacrolimus. Methods： The ABCB1 1236C 〉 T （ rs1128503 ）, ABCB1 2677G 〉 T/A （ rs2032582 ） and ABCB1 3435C 〉 T （ rs1045642 ） genotypes were determined by restriction fragment length polymorphism （RFLP） analysis. The whole blood levels of tacrolimus in renal transplant recipients were measured by ehemiluminescent microparticle immunoassay. Analysis of covarianee （ANCOVA） was performed to determine the difference of tacmlimus C0/D among the various groups. Results： Whether co-administeration of Wuzhi capstiles and tacrolimns or not, tacrolimus C0/D of ABCBI 1236C 〉 T, ABCBI 2677G 〉 T/A and ABCB1 3435C 〉 T genotype and haplotype was without significant difference. Conclusion： When combined with Wuzhi eapsules, ABCB1 1236C 〉 T, ABCB1 2677G 〉 T/A and ABCB1 3435C 〉 T mutation is not associated with tacrolimus C0/D.